PTO/SB/08a (07-09)

Approved for use through 07/31/2012 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Martin A. Gottschalk

31886-705.201

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Application Number 09/825,533 Substitute for form 1449/PTO INFORMATION DISCLOSURE Filing Date April 2, 2001 First Named Inventor Michael R. Hufford STATEMENT BY APPLICANT Art Unit (Use as many sheets as necessary)

Attorney Docket Number

U.S. PATENT DOCUMENTS						
Examiner Cite Initials* No.1		Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1.	US 2002/0143595 A1	10/03/2002	Frank et al.		
	2.	US 2003/0194704 A1	10/16/2003	Penn et al.		
	3.	US 5,412,769	05/02/1995	Maruoka et al.		

Examiner Name

2

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² - Number ² - Kind Code ³ (Finower)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶	
	4.	None					

Continued on the next page with more references.

Evaminer		Date	
- Localitation			
	I /Mariin Gottschalk/		

^{*}EXAMENT: Intel freference considered, whether or not obtains in a conformance with APEP 609. Dow the foreign chained in four non-formance and not considered broken to ordinate the property of the form whether consuments to appeal on a physical variage and intelligence and appeal of the property of the December of the property of the formatter in the property of the formatter intelligence and the property of the property of the formatter intelligence and the

Sheet

1 of

check was the net l'English Inequiag Transition is stateded
This doctétic est inferenties in required to obtain or return a benefit by the public which is to file (and by the USPTO to proceen) an
optionates. Confidentially in general by \$1 U.S.C. 122 and \$1 C.P.T. 14. This collection is entered to sike 2 lover to complete, including gathering, reposing, and incluming the
replication. Confidentially in general by \$1 U.S.C. 122 and \$1 C.P.T. 14. This collection is entered to sike 2 lover to complete, including gathering, reposing, and incluming the
reduced to the confidentially in general confidence of the confidence of the confidential confidence of the confidence of the

PTO/SB/08b (07-09)

Approved for use through 07/31/2012 OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Check the 1 aperwork reconcions rect of 1995, no persons				Complete if Known		
Substitute fo	or form 144	9/PTO		Application Number	09/825,533	
INFORM	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Filing Date	April 2, 2001	
STATEM				First Named Inventor	Michael R. Hufford	
(Use as				Art Unit	3693	
				Examiner Name	Martin A. Gottschalk	
Sheet	2	of	2	Attorney Docket Number	31886-705.201	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Cite Initials* No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.			
	5.	Copy of non-final office action mailed February 19, 2009 in connection with U.S. Patent Application No. 11/844,632.			
	6.	HUFFORD, et al. Collecting reliable and valid real-time patient experience data. Drug Information Journal. 2001; 755-765.			
	7.	HUFFORD, et al. Correspondence between paper and electronic visual analog scales among adult asthmatics. Invivodata. November 9, 2001.			
	8.	Invivodata, Inc. Insights. Third Issue. July 2001.			
	9.	Invivodata. Comparing electronic and paper diary data. Invivodata. November 26, 2001.			
	10.	Invivodata. Guaranteed patient compliance. Insight into patient behavior. Reduced study risks. July 2001.			
	11.	Invivodata. Innovations in Clinical Trial Technologies. Schedule for Seminar. 2001.			
	12.	Invivodata. Prove it - your drug's performance beats the competition. Date?			

Examiner	Bitania Outralia But	Date	44 100 10040		
Signature	/Martin Gottschalk/	Considered	11/20/2010		
ADVIANDED CHARLES AND					

Segments of the Conference of